BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31452449)

  • 1.
    Wu D; Ylli D; Heimlich SL; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2019 Nov; 29(11):1523-1535. PubMed ID: 31452449
    [No Abstract]   [Full Text] [Related]  

  • 2. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
    Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
    Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer.
    Wu D; Plyku D; Kulkarni K; Garcia C; Atkins F; Tefera E; Burman KD; Wartofsky L; Van Nostrand D
    Clin Nucl Med; 2021 Apr; 46(4):283-288. PubMed ID: 33492859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.
    Sakulpisuti C; Charoenphun P; Chamroonrat W
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
    Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (124)I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis.
    Gulec SA; Kuker RA; Goryawala M; Fernandez C; Perez R; Khan-Ghany A; Apaza A; Harja E; Harrell M
    Thyroid; 2016 Mar; 26(3):441-8. PubMed ID: 26857905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
    Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis.
    Caetano R; Bastos CR; de Oliveira IA; da Silva RM; Fortes CP; Pepe VL; Reis LG; Braga JU
    Head Neck; 2016 Feb; 38(2):316-27. PubMed ID: 25251544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis.
    Santhanam P; Taieb D; Solnes L; Marashdeh W; Ladenson PW
    Clin Endocrinol (Oxf); 2017 May; 86(5):645-651. PubMed ID: 28160320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
    Dong MJ; Liu ZF; Zhao K; Ruan LX; Wang GL; Yang SY; Sun F; Luo XG
    Nucl Med Commun; 2009 Aug; 30(8):639-50. PubMed ID: 19512954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
    Weber M; Binse I; Nagarajah J; Bockisch A; Herrmann K; Jentzen W
    Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):235-252. PubMed ID: 31298014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer.
    Samnick S; Al-Momani E; Schmid JS; Mottok A; Buck AK; Lapa C
    Clin Nucl Med; 2018 Mar; 43(3):162-167. PubMed ID: 29356744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.